Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.
Insulin-induced stimulation of muscle glucose uptake (MGU) is impaired in people with type 2 diabetes. To determine whether insulin-induced stimulation of splanchnic glucose uptake (SGU) is also impaired, we simultaneously measured leg glucose uptake (LGU) and SGU in 14 nondiabetic subjects and 16 subjects with type 2 diabetes using a combined organ catheterization-tracer infusion technique. Glucose was clamped at approximately 9.3 mmol/l, while insulin concentrations were maintained at approximately 72 pmol/l (low) and approximately 150 pmol/l (high) for 3 h each. Endogenous hormone secretion was inhibited with somatostatin. Total body glucose disappearance was lower (P < 0.01) and glucose production higher (P < 0.01) during both insulin infusions in the diabetic compared with the nondiabetic subjects, indicating insulin resistance. Splanchnic glucose production was higher (P < 0.05) in the diabetic subjects during the low but not the high insulin infusion. SGU was slightly lower in the diabetic than in the nondiabetic subjects during the low insulin infusion and 50-60% lower (P < 0.05) during the high insulin infusion. LGU (P < 0.001), but not SGU, was inversely correlated with the degree of visceral adiposity. The contribution of the indirect pathway to hepatic glycogen synthesis did not differ in the diabetic and nondiabetic subjects. In contrast, both flux through the UDP-glucose pool (P < 0.05) and the contribution of the direct pathway to glycogen synthesis (P < 0.01) were lower in the diabetic than in the nondiabetic subjects, indicating decreased uptake and/or phosphorylation of extracellular glucose. On the other hand, glycogenolysis was equally suppressed in both groups. In summary, type 2 diabetes impairs the ability of insulin to stimulate both MGU and SGU. The defect appears to reside at a proximal (e.g., glucokinase) metabolic step and is not related to the degree of visceral adiposity. These data suggest that impaired hepatic glucose uptake as well as MGU contribute to hyperglycemia in people with type 2 diabetes.
Basu
A
A
Department of Endocrinology, Mayo Foundation, Rochester, Minnesota 55905, USA.
Basu
R
R
Shah
P
P
Vella
A
A
Johnson
C M
CM
Nair
K S
KS
Jensen
M D
MD
Schwenk
W F
WF
Rizza
R A
RA
D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology*; D005934:Glucagon / Q000096:biosynthesis / Q000097:blood; D005941:Glucokinase / Q000378:metabolism; D005947:Glucose / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood / Q000502:physiology*; D007866:Leg / Q000098:blood supply; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism*; D019308:Palmitic Acid / Q000097:blood; D012016:Reference Values; D014530:Uridine Diphosphate / Q000378:metabolism; D014781:Viscera / Q000378:metabolism*
D001786:Blood Glucose; D007328:Insulin; D019382:Human Growth Hormone; D019308:Palmitic Acid; D014530:Uridine Diphosphate; D005934:Glucagon; D005941:Glucokinase; D005947:Glucose